By Scott Kanowsky
Investing.com -- Shares in Novavax Inc (NASDAQ: NVAX ) shed over a fourth of their value in pre-market U.S. trading on Wednesday after the COVID-19 vaccine maker warned of substantial doubt around its future in the wake of lower-than-expected fourth-quarter revenue.
The Maryland-based company flagged "significant uncertainty," particularly surrounding its 2023 sales, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi.
"[S]ubstantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued," Novavax said in a statement.
A decision by the U.S. government not to extend an agreement with Novavax past December 2023 places $416 million at risk, according to a Reuters report. The result of the Gavi arbitration may also require the firm to refund about $700M it received from the group, the news agency said.
Meanwhile, expenses nearly doubled to $162M due to a strategy that will see Novavax move away from government contracts and attempt to start commercial sales of its COVID vaccine program. The business subsequently reported a net loss in the three months to the end of December of $182M, or $2.28 per share.
Analysts at Jefferies noted that while they continue to see value in Novavax's protein-based COVID jab, there are still a few uncertainties around the near-term outlook.
The slide in Novavax's shares put them on pace for their worst day in more than two months. The stock's market value had previously climbed to more than $20 billion at one point as it raced to develop a COVID vaccine, but has since slumped to less than $800M.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.